文献速递产科

Foley联合前列腺素与Foley联合缩宫素促宫颈成熟的网状Meta分析

Combination of Foley and prostaglandins versus Foley and oxytocin for cervical ripening: a network meta-analysis.
PubMed 文献 · Am J Obstet Gynecol · 2020-05-07

本研究通过网状Meta分析比较Foley联合前列腺素与Foley联合缩宫素对促宫颈成熟至阴道分娩时间的影响,共纳入30项随机对照试验6465名孕妇。结果显示Foley联合缩宫素较单用Foley缩短阴道分娩时间4.2小时,而Foley联合前列腺素与Foley联合缩宫素之间无显著差异,但Foley联合前列腺素组子宫内膜炎发生率较高。

要点

  • Foley联合缩宫素较单用Foley缩短阴道分娩时间4.2小时(95%CI -6.5至-1.9)。
  • Foley联合前列腺素与Foley联合缩宫素在阴道分娩时间上无差异(1.3小时,95%CI -2.0至4.7)。
  • Foley联合前列腺素组子宫内膜炎发生率较高,但受样本量限制。

核心结论

  • Foley联合米索前列醇、Foley联合地诺前列酮与Foley联合缩宫素在阴道分娩时间上相似。
  • 地诺前列酮比较受小样本限制,但提示较Foley联合米索前列醇或缩宫素分娩时间更长。

研究设计与样本

  • 网状Meta分析(PROSPERO CRD42018081948),纳入30项随机对照试验共6465名孕妇。
  • 检索数据库从建库至2020年3月,纳入比较Foley联合缩宫素与Foley联合前列腺素(米索前列醇或地诺前列酮)的随机试验。
  • 纳入孕周>24周活胎,初产妇和经产妇一起分析,排除准随机、队列研究及其他促宫颈成熟联合方法。

主要发现

  • 与单用Foley相比,Foley联合缩宫素缩短阴道分娩时间4.2小时(95%CI -6.5至-1.9)。
  • Foley联合前列腺素与Foley联合缩宫素头对头比较,阴道分娩时间无差异(1.3小时,95%CI -2.0至4.7)。
  • 两组在剖宫产率、绒毛膜羊膜炎、硬膜外使用、子宫过度刺激、产后出血、胎粪、新生儿ICU入住及5分钟Apgar评分<7方面无差异,但Foley联合前列腺素组子宫内膜炎发生率较高。

关键数值与推荐

  • 主要结局为从引产到阴道分娩的平均时间(小时)。
  • 次要结局包括引产至分娩时间、24小时内分娩、剖宫产、绒毛膜羊膜炎、子宫内膜炎、硬膜外使用、子宫过度刺激、产后出血、胎粪、新生儿ICU入住及5分钟Apgar评分<7。

临床怎么用

  • Foley联合缩宫素或Foley联合前列腺素均可用于促宫颈成熟,两者在阴道分娩时间上无显著差异。
  • 选择联合方案时需权衡子宫内膜炎风险,Foley联合前列腺素组子宫内膜炎发生率较高。
  • 地诺前列酮联合Foley可能分娩时间更长,需结合临床具体情况个体化选择。

局限性

  • 地诺前列酮相关比较受小样本量限制。
  • 间接比较中研究报道方式多样及感染性疾病定义不一致可能影响结果。
  • 样本量限制了对孕产妇和新生儿不良事件差异的检测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Trial and meta-analysis data revealed a reduction in time to delivery for Foley and prostaglandins or Foley and oxytocin vs Foley alone. However, there are limited data for the comparison of the 2 combination methods against each other. OBJECTIVE: This study aimed to determine whether Foley and prostaglandins or Foley and oxytocin decrease the time to vaginal delivery using a network meta-analysis. STUDY DESIGN: A network meta-analysis (PROSPERO CRD42018081948) was performed comparing Foley and prostaglandins (prostaglandin E1 or prostaglandin E2) vs Foley and oxytocin for cervical ripening. Foley alone and prostaglandins alone were used as nodes for indirect comparison. Database searches were performed from inception to March 2020 with data abstracted from published manuscripts. Eligibility criteria included randomized trials comparing Foley and oxytocin with Foley and prostaglandins (misoprostol or dinoprostone). Trials that compared Foley catheter or prostaglandins with a combination of Foley and prostaglandins or Foley and concurrent oxytocin were also included. Nulliparous and multiparous women were analyzed together. Foley catheters of any catheter material or size and >24 weeks' gestational age with a live fetus were included. Quasi-randomized, cohorts, and other combination methods for cervical ripening were not included. Prostaglandin E1 and prostaglandin E2 combined methods were analyzed separately in a planned subanalysis. The primary outcome was the mean time from induction to vaginal delivery in hours. Secondary outcomes included time from induction to delivery, delivery within 24 hours, cesarean delivery, chorioamnionitis, endometritis, epidural use, tachysystole, postpartum hemorrhage, meconium, neonatal intensive care unit admission, and 5-minute appearance, pulse, grimace, activity, and respiration score of <7. Data were analyzed as a network meta-analysis using multivariate meta-regression. RESULTS: A total of 30 randomized controlled trials with a total of 6465 women were considered eligible for inclusion in this network meta-analysis. When compared with Foley alone, the use of Foley-oxytocin reduced the time to vaginal delivery by 4.2 hours (mean duration, -4.2 hours; 95% confidence interval, -6.5 to -1.9). Foley-prostaglandins reduced the time to vaginal delivery compared with Foley but did not meet statistical significance (mean duration, -2.9 hours; 95% confidence interval, -5.7 to 0.0; P=.05). When compared head-to-head, there was no difference in the time to vaginal delivery between Foley-prostaglandins and Foley-oxytocin (mean duration, 1.3 hours; 95% confidence interval, -2.0 to 4.7). There was no difference in the rate of cesarean delivery, chorioamnionitis, epidural, tachysystole, postpartum hemorrhage, meconium, neonatal intensive care unit admissions, or 5-minute appearance, pulse, grimace, activity, and respiration score of <7 for Foley-prostaglandins vs Foley-oxytocin, although the rate of endometritis was high for Foley-prostaglandins. In the subanalysis by prostaglandin type, there was no difference in the time to vaginal delivery for Foley-misoprostol vs Foley-dinoprostone vs Foley-oxytocin. However, Foley-dinoprostone had a definite trend toward longer time to all deliveries compared with that of both Foley-misoprostol and Foley-oxytocin (P=.05). CONCLUSION: Time to vaginal delivery was similar when comparing Foley with combined misoprostol, combined dinoprostone, and combined oxytocin. Dinoprostone comparisons are limited by small sample size but suggest longer time to delivery compared with Foley and misoprostol or oxytocin. No significant differences were observed in maternal or neonatal adverse events except for endometritis, but this was limited by the sample size, varied reporting of studies used in the indirect comparisons, and definitions of infectious morbidity use in the studies.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Orr L, Reisinger-Kindle K, Roy A, et al. Combination of Foley and prostaglandins versus Foley and oxytocin for cervical ripening: a network meta-analysis. Am J Obstet Gynecol. 2020. PMID: 32387325. doi:10.1016/j.ajog.2020.05.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。